Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study
Authors:
- Fumiya YoneyamaFYFumiya Yoneyama
- Naoki FujitaNFNaoki Fujita
- Yohei KawashimaYKYohei Kawashima
- Masanao ShinoharaMSMasanao Shinohara
- Ryuji TabataRTRyuji Tabata
- Ryuma TanakaRTRyuma Tanaka
- Takuya OishiTOTakuya Oishi
- Hikari MiuraHMHikari Miura
- Kyo TogashiKTKyo Togashi
- Kazutaka OkitaKOKazutaka Okita
- Hirotaka HoriguchiHHHirotaka Horiguchi
- Toshikazu TanakaTTToshikazu Tanaka
- 8 July 2025
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (9) , 1858-1865
Abstract
Background Although three phase III trials demonstrated significant oncological benefits of novel androgen receptor signaling inhibitors (ARSIs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC), trends in novel ARSI use have been sparsely documented. Moreover, the safety and oncological benefits of novel ARSIs in real-world nmCRPC settings remain unclear. Methods This multicenter retrospective study evaluated 318 consecutive patients with nmCRPC treated between 2001 and 2024. Trends in the use of novel ARSIs were analyzed. Adverse events associated with novel ARSIs were assessed using the Common Terminology Criteria for Adverse Events version 5.0. Multivariable Cox proportional hazards regression analyses were conducted to evaluate the effects of novel ARSIs on metastasis-free survival (MFS) and overall survival (OS). Results The median age and follow-up period after nmCRPC diagnosis were 77 years and 46 months, respectively. Of the 318 patients, 231 (73%) received novel ARSI treatment at some point during nmCRPC management. First-line use of novel ARSIs gradually increased following their initial approval for nmCRPC in 2014. The rate of first-line novel ARSI use was significantly higher in 2020–2024 than in 2014–2019 (68% vs. 33%, P < 0.001). The incidence rates of any-grade and grade ≥ 3 adverse events associated with novel ARSIs were 23% and 2.2%, respectively. After adjusting for confounding variables, novel ARSIs were independently and significantly associated with prolonged MFS and OS. Conclusions Novel ARSIs have become a primary treatment strategy for nmCRPC in real-world settings, demonstrating both safety and significant oncological benefits.Keywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (25K12244)
This publication has 24 references indexed in Scilit:
- Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancerCancer Medicine, 2024
- Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerJAMA Network Open, 2024
- Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate CancerJAMA Network Open, 2024
- Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real worldInternational Urology and Nephrology, 2024
- Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective studyInternational Journal of Clinical Oncology, 2024
- A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, CanadaClinical Genitourinary Cancer, 2024
- Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?European Urology Oncology, 2023
- Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapyWorld Journal of Urology, 2022
- Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in JapanInternational Journal of Clinical Oncology, 2021
- The hypothalamic–pituitary–gonadal axis and prostate cancer: implications for androgen deprivation therapyWorld Journal of Urology, 2013